{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:36:34Z","timestamp":1792798594190,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P30GM114736"],"award-info":[{"award-number":["P30GM114736"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s11914-020-00620-4","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T09:03:20Z","timestamp":1598432600000},"page":"515-525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Bone-Specific Drug Delivery for Osteoporosis and Rare Skeletal Disorders"],"prefix":"10.1007","volume":"18","author":[{"given":"Kazuki","family":"Sawamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. V\u00edctor","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lica Mar\u00eda","family":"Herre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Otero-Espinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Couce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos J.","family":"Alm\u00e9ciga-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0673-2160","authenticated-orcid":false,"given":"Shunji","family":"Tomatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"#cr-split#-620_CR1.1","doi-asserted-by":"crossref","unstructured":"Farrell KB, Karpeisky A, Thamm DH, Zinnen S. Bisphosphonate conjugation for bone specific drug targeting [Internet]. Bone Rep. 2018:47-60 Elsevier Inc","DOI":"10.1016\/j.bonr.2018.06.007"},{"key":"#cr-split#-620_CR1.2","unstructured":"[cited 2020 Apr 16]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29992180."},{"key":"620_CR2","doi-asserted-by":"crossref","unstructured":"Riggs BL, Melton LJ. Involutional osteoporosis. N Engl J Med. 1986:1676\u201386.","DOI":"10.1056\/NEJM198606263142605"},{"key":"620_CR3","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/jbmr.2269","volume":"29","author":"NC Wright","year":"2014","unstructured":"Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29:2520\u20136 [Internet]. John Wiley and Sons Inc. [cited 2020 Apr 16]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24771492.","journal-title":"J Bone Miner Res"},{"key":"620_CR4","doi-asserted-by":"publisher","unstructured":"Stapleton M, Sawamoto K, Almeciga-Diaz CJ, Mackenzie WG, Mason RW, Orii T, et al. Development of bone targeting drugs. Int J Mol Sci. 2017;18. Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA. mstaple@udel.edu.; Nemours\/Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA. mstaple@udel.edu.; Nemours\/Alfred I. duPont Hospital for Children, Wilmington. https:\/\/doi.org\/10.3390\/ijms18071345.","DOI":"10.3390\/ijms18071345"},{"key":"620_CR5","doi-asserted-by":"crossref","unstructured":"Carbone EJ, Rajpura K, Allen BN, Cheng E, Ulery BD, Lo KWH. Osteotropic nanoscale drug delivery systems based on small molecule bone-targeting moieties. Nanomed Nanotechnol Biol Med. 2017:37\u201347 Elsevier Inc.","DOI":"10.1016\/j.nano.2016.08.015"},{"key":"620_CR6","doi-asserted-by":"crossref","unstructured":"Wang D, Miller SC, Kope\u010dkov\u00e1 P, Kope\u010dek J. Bone-targeting macromolecular therapeutics. Adv Drug Deliv Rev. 2005:1049\u201376.","DOI":"10.1016\/j.addr.2004.12.011"},{"key":"620_CR7","doi-asserted-by":"crossref","unstructured":"Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008:S131 American Society of Nephrology.","DOI":"10.2215\/CJN.04151206"},{"key":"620_CR8","doi-asserted-by":"crossref","unstructured":"Khan I, Saeed K, Khan I. Nanoparticles: properties, applications and toxicities. Arab J Chem. 2019:908\u201331 Elsevier B.V.","DOI":"10.1016\/j.arabjc.2017.05.011"},{"key":"620_CR9","doi-asserted-by":"crossref","unstructured":"Russell RGG. Bisphosphonates: the first 40 years. Bone. 2011:2\u201319.","DOI":"10.1016\/j.bone.2011.04.022"},{"key":"620_CR10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","volume":"38","author":"GH Nancollas","year":"2006","unstructured":"Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38:617\u201327.","journal-title":"Bone."},{"key":"620_CR11","doi-asserted-by":"crossref","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008:1032\u201345 Elsevier Ltd.","DOI":"10.4065\/83.9.1032"},{"key":"620_CR12","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1021\/mp8002368","volume":"6","author":"MR Doschak","year":"2009","unstructured":"Doschak MR, Kucharski CM, Wright JEI, Zernicke RF, Uludag H. Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis. Mol Pharm. 2009;6:634\u201340 [Internet]. [cited 2020 Apr 16]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19718808.","journal-title":"Mol Pharm"},{"key":"620_CR13","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/jps.22773","volume":"101","author":"Y Zheng","year":"2012","unstructured":"Zheng Y, Nishikawa M, Ikemura M, Yamashita F, Hashida M. Development of bone-targeted catalase derivatives for inhibition of bone metastasis of tumor cells in mice. J Pharm Sci. 2012;101:552\u20137 [Internet]. John Wiley and Sons Inc. [cited 2020 Apr 16]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21953593.","journal-title":"J Pharm Sci"},{"key":"620_CR14","doi-asserted-by":"crossref","unstructured":"Katsumi H, Sano JI, Nishikawa M, Hanzawa K, Sakane T, Yamamoto A. Molecular design of bisphosphonate-modified proteins for efficient bone targeting in vivo. PLoS One. 2015;10 Public Library of Science.","DOI":"10.1371\/journal.pone.0135966"},{"key":"620_CR15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/03008208909002412","volume":"23","author":"WT Butler","year":"1989","unstructured":"Butler WT. The nature and significance of osteopontin. Connect Tissue Res. 1989;23:123\u201336 Informa Healthcare.","journal-title":"Connect Tissue Res"},{"key":"620_CR16","doi-asserted-by":"crossref","first-page":"8819","DOI":"10.1073\/pnas.83.23.8819","volume":"83","author":"A Oldberg","year":"1986","unstructured":"Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A. 1986;83:8819\u201323.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"620_CR17","doi-asserted-by":"crossref","first-page":"19430","DOI":"10.1016\/S0021-9258(19)77651-0","volume":"263","author":"A Oldberg","year":"1988","unstructured":"Oldberg A, Franzen A, Heinegard D. The primary structure of a cell-binding bone sialoprotein. J Biol Chem. 1988;263:19430\u20132.","journal-title":"J Biol Chem"},{"key":"620_CR18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0167-4838(95)00190-5","volume":"1292","author":"R Fujisawa","year":"1996","unstructured":"Fujisawa R, Wada Y, Nodasaka Y, Kuboki Y. Acidic amino acid-rich sequences as binding sites of osteonectin to hydroxyapatite crystals. Biochim Biophys Acta Protein Struct Mol Enzymol. 1996;1292:53\u201360 Elsevier B.V.","journal-title":"Biochim Biophys Acta Protein Struct Mol Enzymol"},{"key":"620_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3109\/10611860108997922","volume":"9","author":"T Sekido","year":"2001","unstructured":"Sekido T, Sakura N, Higashi Y, Miya K, Nitta Y, Nomura M, et al. Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential. J Drug Target. 2001;9:111\u201321. [Internet]. Taylor & Francis Available from. https:\/\/doi.org\/10.3109\/10611860108997922.","journal-title":"J Drug Target"},{"key":"620_CR20","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.addr.2012.01.012","volume":"64","author":"SA Low","year":"2012","unstructured":"Low SA, Kopecek J. Targeting polymer therapeutics to bone. Adv Drug Deliv Rev. 2012;64:1189\u2013204 Department of Bioengineering, University of Utah, Salt Lake City, UT 84112, USA.: Elsevier B.V.","journal-title":"Adv Drug Deliv Rev"},{"key":"620_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/10717544.2014.913325","volume":"23","author":"R Vinay","year":"2016","unstructured":"Vinay R, KusumDevi V. Potential of targeted drug delivery system for the treatment of bone metastasis. Drug Deliv. 2016;23:21\u20139. [Internet]. Taylor & Francis; Available from. https:\/\/doi.org\/10.3109\/10717544.2014.913325.","journal-title":"Drug Deliv"},{"key":"620_CR22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nm.2617","volume":"18","author":"G Zhang","year":"2012","unstructured":"Zhang G, Guo B, Wu H, Tang T, Zhang BT, Zheng L, et al. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med. 2012;18:307\u201314 Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong, China.","journal-title":"Nat Med"},{"key":"620_CR23","doi-asserted-by":"crossref","unstructured":"Sipila S, Tormakangas T, Sillanpaa E, Aukee P, Kujala UM, Kovanen V, et al. Muscle and bone mass in middle-aged women: role of menopausal status and physical activity. J Cachexia Sarcopenia Muscle. 2020; Gerontology Research Center, Faculty of Sport and Health Sciences, University of Jyvaskyla, Jyvaskyla, Finland.; Gerontology Research Center, Faculty of Sport and Health Sciences, University of Jyvaskyla, Jyvaskyla, Finland.; Gerontology Research Center, : The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.","DOI":"10.1002\/jcsm.12547"},{"key":"620_CR24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2011.10.001","volume":"161","author":"T Luhmann","year":"2012","unstructured":"Luhmann T, Germershaus O, Groll J, Meinel L. Bone targeting for the treatment of osteoporosis. J Control Release. 2012;161:198\u2013213 Institute for Pharmacy and Food Chemistry, University of Wurzburg, Am Hubland, DE-97074 Wurzburg, Germany.: Elsevier B.V.","journal-title":"J Control Release"},{"key":"620_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41390-018-0095-8","volume":"84","author":"CJ Alm\u00e9ciga-D\u00edaz","year":"2018","unstructured":"Alm\u00e9ciga-D\u00edaz CJ, Monta\u00f1o AM, Barrera LA, Tomatsu S. Tailoring the AAV2 capsid vector for bone-targeting. Pediatr Res. 2018;84:545\u201351. [Internet]. Available from. https:\/\/doi.org\/10.1038\/s41390-018-0095-8.","journal-title":"Pediatr Res"},{"key":"620_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41434-019-0086-3","volume":"27","author":"CJ Alm\u00e9ciga-Diaz","year":"2020","unstructured":"Alm\u00e9ciga-Diaz CJ, Barrera LA. Design and applications of gene therapy vectors for mucopolysaccharidosis in Colombia. Gene Ther. 2020;27:104\u20137. [Internet] Available from. https:\/\/doi.org\/10.1038\/s41434-019-0086-3.","journal-title":"Gene Ther"},{"key":"620_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nrrheum.2012.17","volume":"8","author":"K Ray","year":"2012","unstructured":"Ray K. Silencing inhibitors of bone formation. Nat Rev Rheumatol. 2012;8:122. [Internet]. Available from. https:\/\/doi.org\/10.1038\/nrrheum.2012.17.","journal-title":"Nat Rev Rheumatol"},{"key":"620_CR28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.22203\/eCM.v031a23","volume":"31","author":"I Alencastre","year":"2016","unstructured":"Alencastre I, Sousa D, Alves C, Leit\u00e3o L, Neto E, Aguiar P, et al. Delivery of pharmaceutics to bone: nanotechnologies, high-throughput processing and in silico mathematical models. Eur Cell Mater. 2016;31:355\u201381.","journal-title":"Eur Cell Mater"},{"key":"620_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3109\/10717544.2012.714809","volume":"19","author":"B Jiang","year":"2012","unstructured":"Jiang B, Cao J, Zhao J, He D, Pan J, Li Y, et al. Dual-targeting delivery system for bone cancer: synthesis and preliminary biological evaluation. Drug Deliv. 2012;19:317\u201326. [Internet]. Taylor & Francis. Available from. https:\/\/doi.org\/10.3109\/10717544.2012.714809.","journal-title":"Drug Deliv"},{"key":"620_CR30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/os.12238","volume":"8","author":"CJ Li","year":"2016","unstructured":"Li CJ, Liu XZ, Zhang L, Chen LB, Shi X, Wu SJ, et al. Advances in bone-targeted drug delivery systems for neoadjuvant chemotherapy for osteosarcoma. Orthop Surg. 2016;8:105\u201310 Department of Orthopaedics, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China.; Department of Orthopaedics, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China.; Department of Orthopaedics, School of Medicine, J: Chinese Orthopaedic Association and John Wiley & Sons Australia, Ltd.","journal-title":"Orthop Surg"},{"key":"620_CR31","doi-asserted-by":"crossref","unstructured":"Aoki K, Alles N, Soysa N, Ohya K. Peptide-based delivery to bone [Internet]. Adv Drug Deliv Rev. 2012:1220\u201338 [cited 2020 Jul 13]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22709649\/.","DOI":"10.1016\/j.addr.2012.05.017"},{"key":"620_CR32","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1089\/ten.tea.2014.0313","volume":"21","author":"TBL Nguyen","year":"2015","unstructured":"Nguyen TBL, Min YK, Lee B-T. Nanoparticle biphasic calcium phosphate loading on gelatin-pectin scaffold for improved bone regeneration. Tissue Eng Part A. 2015;21:1376\u201387 [Internet]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25602709.","journal-title":"Tissue Eng Part A"},{"key":"620_CR33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biomaterials.2016.04.026","volume":"97","author":"X Ma","year":"2016","unstructured":"Ma X, Gong N, Zhong L, Sun J, Liang X-J. Future of nanotherapeutics: targeting the cellular sub-organelles. Biomaterials. 2016;97:10\u201321 [Internet]. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961216301375.","journal-title":"Biomaterials"},{"key":"620_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2017.02.012","volume":"252","author":"M Parent","year":"2017","unstructured":"Parent M, Baradari H, Champion E, Damia C, Viana-Trecant M. Design of calcium phosphate ceramics for drug delivery applications in bone diseases: a review of the parameters affecting the loading and release of the therapeutic substance. J Control Release. 2017;252:1\u201317 [Internet]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28232225.","journal-title":"J Control Release"},{"key":"620_CR35","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10856-007-3185-4","volume":"19","author":"AJ Melville","year":"2008","unstructured":"Melville AJ, Rodr\u00edguez-Lorenzo LM, Forsythe JS. Effects of calcination temperature on the drug delivery behaviour of ibuprofen from hydroxyapatite powders. J Mater Sci Mater Med. 2008;19:1187\u201395 [Internet]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17701302.","journal-title":"J Mater Sci Mater Med"},{"key":"620_CR36","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1016\/j.biomaterials.2003.10.081","volume":"25","author":"T Matsumoto","year":"2004","unstructured":"Matsumoto T, Okazaki M, Inoue M, Yamaguchi S, Kusunose T, Toyonaga T, et al. Hydroxyapatite particles as a controlled release carrier of protein. Biomaterials. 2004;25:3807\u201312 [Internet]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15020156.","journal-title":"Biomaterials"},{"key":"620_CR37","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1016\/j.actbio.2014.06.017","volume":"10","author":"K Lin","year":"2014","unstructured":"Lin K, Wu C, Chang J. Advances in synthesis of calcium phosphate crystals with controlled size and shape. Acta Biomater. 2014;10:4071\u2013102 [Internet]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24954909.","journal-title":"Acta Biomater"},{"key":"620_CR38","doi-asserted-by":"publisher","unstructured":"Uskokovi\u0107 V, Batarni SS, Schweicher J, King A, Desai TA. Effect of calcium phosphate particle shape and size on their antibacterial and osteogenic activity in the delivery of antibiotics in vitro. ACS Appl Mater Interfaces 2013;5(7):2422\u201331. https:\/\/doi.org\/10.1021\/am4000694","DOI":"10.1021\/am4000694"},{"key":"620_CR39","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1016\/S0142-9612(03)00366-1","volume":"24","author":"B Feng","year":"2003","unstructured":"Feng B, Weng J, Yang BC, Qu SX, Zhang XD. Characterization of surface oxide films on titanium and adhesion of osteoblast. Biomaterials. 2003;24:4663\u201370 [Internet] Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961203003661.","journal-title":"Biomaterials"},{"key":"620_CR40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1039\/C0CS00003E","volume":"40","author":"LYT Chou","year":"2011","unstructured":"Chou LYT, Ming K, Chan WCW. Strategies for the intracellular delivery of nanoparticles. Chem Soc Rev. 2011;40:233\u201345 [Internet]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20886124.","journal-title":"Chem Soc Rev"},{"key":"620_CR41","doi-asserted-by":"crossref","unstructured":"Kruger CA, Abrahamse H. Utilisation of targeted nanoparticle photosensitiser drug delivery systems for the enhancement of photodynamic therapy [Internet]. Molecules. 2018; MDPI AG. [Cited 2020 Apr 17]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30322132.","DOI":"10.3390\/molecules23102628"},{"key":"620_CR42","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2174\/13892002113149990008","volume":"14","author":"I Ojea-Jimenez","year":"2013","unstructured":"Ojea-Jimenez I, Comenge J, Garcia-Fernandez L, Megson Z, Casals E, Puntes V. Engineered inorganic nanoparticles for drug delivery applications. Curr Drug Metab. 2013;14:518\u201330 Bentham Science Publishers Ltd.","journal-title":"Curr Drug Metab"},{"key":"620_CR43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jconrel.2007.06.003","volume":"122","author":"S-W Choi","year":"2007","unstructured":"Choi S-W, Kim J-H. Design of surface-modified poly(D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. J Control Release. 2007;122:24\u201330.","journal-title":"J Control Release"},{"key":"620_CR44","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jconrel.2011.11.020","volume":"158","author":"K Ramanlal Chaudhari","year":"2012","unstructured":"Ramanlal Chaudhari K, Kumar A, Megraj Khandelwal VK, Ukawala M, Manjappa AS, Mishra AK, et al. Bone metastasis targeting: a novel approach to reach bone using zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel. J Control Release. 2012;158:470\u20138 [Internet]. [cited 2020 Apr 17]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22146683.","journal-title":"J Control Release"},{"key":"620_CR45","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2174\/156800910793605767","volume":"10","author":"M Salerno","year":"2010","unstructured":"Salerno M, Cenni E, Fotia C, Avnet S, Granchi D, Castelli F, et al. Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Curr Cancer Drug Targets. 2010;10:649\u201359 [Internet]. Bentham Science Publishers Ltd. [cited 2020 Apr 17]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20578992.","journal-title":"Curr Cancer Drug Targets"},{"key":"620_CR46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/jfb3010079","volume":"3","author":"R Pignatello","year":"2012","unstructured":"Pignatello R, Sarpietro MG, Castelli F. Synthesis and biological evaluation of a new polymeric conjugate and nanocarrier with osteotropic properties. J Funct Biomater. 2012;3:79\u201399 MDPI AG.","journal-title":"J Funct Biomater"},{"key":"620_CR47","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/adhm.201300465","volume":"3","author":"SW Morton","year":"2014","unstructured":"Morton SW, Shah NJ, Quadir MA, Deng ZJ, Poon Z, Hammond PT. Osteotropic therapy via targeted layer-by-layer nanoparticles. Adv Healthc Mater. 2014;3:867\u201375 Wiley-VCH Verlag.","journal-title":"Adv Healthc Mater"},{"key":"620_CR48","doi-asserted-by":"crossref","first-page":"10287","DOI":"10.1073\/pnas.1401337111","volume":"111","author":"A Swami","year":"2014","unstructured":"Swami A, Reagan MR, Basto P, Mishima Y, Kamaly N, Glavey S, et al. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A. 2014;111:10287\u201392 [Internet]. National Academy of Sciences. [cited 2020 Apr 17]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24982170.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"620_CR49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0378-5122(94)00869-9","volume":"21","author":"G Rannevik","year":"1995","unstructured":"Rannevik G, Jeppsson S, Johnell O, Bjerre B, Laurell-Borulf Y, Svanberg L. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas. 1995;21:103\u201313.","journal-title":"Maturitas."},{"key":"620_CR50","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1210\/jc.2005-1836","volume":"91","author":"MFR Sowers","year":"2006","unstructured":"Sowers MFR, Jannausch M, McConnell D, Little R, Greendale GA, Finkelstein JS, et al. Hormone predictors of bone mineral density changes during the menopausal transition. J Clin Endocrinol Metab. 2006;91:1261\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"620_CR51","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1210\/endo.142.3.8024","volume":"142","author":"K Yokogawa","year":"2001","unstructured":"Yokogawa K, Miya K, Sekido T, Higashi Y, Nomura M, Fujisawa R, et al. Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology. 2001;142:1228\u201333 Department of Hospital Pharmacy, School of Medicine, Kanazawa University, Kanazawa 920\u20138641, Japan.","journal-title":"Endocrinology"},{"key":"620_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00774-008-0004-z","volume":"27","author":"J Ishizaki","year":"2009","unstructured":"Ishizaki J, Waki Y, Takahashi-Nishioka T, Yokogawa K, Miyamoto K. Selective drug delivery to bone using acidic oligopeptides. J Bone Miner Metab. 2009;27:1\u20138. [Internet]. Available from. https:\/\/doi.org\/10.1007\/s00774-008-0004-z.","journal-title":"J Bone Miner Metab"},{"key":"620_CR53","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s13346-017-0407-2","volume":"7","author":"Y Yang","year":"2017","unstructured":"Yang Y, Aghazadeh-Habashi A, Panahifar A, Wu Y, Bhandari KH, Doschak MR. Bone-targeting parathyroid hormone conjugates outperform unmodified PTH in the anabolic treatment of osteoporosis in rats. Drug Deliv Transl Res. 2017;7:482\u201396 [Internet]. Springer Verlag. [cited 2020 Apr 16]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28721611.","journal-title":"Drug Deliv Transl Res"},{"key":"620_CR54","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2174\/156720181201150310154026","volume":"12","author":"K Bhandari","year":"2015","unstructured":"Bhandari K, Asghar W, Newa M, Jamali F, Doschak M. Evaluation of bone targeting salmon calcitonin analogues in rats developing osteoporosis and adjuvant arthritis. Curr Drug Deliv. 2015;12:98\u2013107 Bentham Science Publishers Ltd.","journal-title":"Curr Drug Deliv"},{"key":"620_CR55","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0968-0896(99)00045-0","volume":"7","author":"L Gil","year":"1999","unstructured":"Gil L, Han Y, Opas EE, Rodan GA, Ruel R, Seedor JG, et al. Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis. Bioorg Med Chem. 1999;7:901\u201319.","journal-title":"Bioorg Med Chem"},{"key":"620_CR56","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1211\/0022357001773652","volume":"52","author":"N Tsushima","year":"2000","unstructured":"Tsushima N, Yabuki M, Harada H, Katsumata T, Kanamaru H, Nakatsuka I, et al. Tissue distribution and pharmacological potential of SM-16896, a novel oestrogen-bisphosphonate hybrid compound*. J Pharm Pharmacol. 2000;52:27\u201337 Wiley.","journal-title":"J Pharm Pharmacol"},{"key":"620_CR57","doi-asserted-by":"crossref","unstructured":"Tomatsu S, Monta\u00f1o AM, Oikawa H, Giugliani R, Harmatz PR, Smith M, et al. Chapter 126 impairment of body growth in mucopolysaccharidoses. 2011.","DOI":"10.1007\/978-1-4419-1795-9_126"},{"key":"620_CR58","doi-asserted-by":"crossref","unstructured":"Melbouci M, Mason RW, Suzuki Y, Fukao T, Orii T, Tomatsu S. Growth impairment in mucopolysaccharidoses. Mol Genet Metab. 2018:1\u201310 Academic Press Inc.","DOI":"10.1016\/j.ymgme.2018.03.004"},{"key":"620_CR59","doi-asserted-by":"crossref","unstructured":"Tomatsu S, Alm\u00e9ciga-D\u00edaz CJ, Monta\u00f1o AM, Yabe H, Tanaka A, Dung VC, et al. Therapies for the bone in mucopolysaccharidoses. Mol Genet Metab. 2015:94\u2013109 Academic Press Inc.","DOI":"10.1016\/j.ymgme.2014.12.001"},{"key":"620_CR60","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ymgme.2015.11.013","volume":"117","author":"HH Kecskemethy","year":"2016","unstructured":"Kecskemethy HH, Kubaski F, Harcke HT, Tomatsu S. Bone mineral density in MPS IV A (Morquio syndrome type A). Mol Genet Metab. 2016;117:144\u20139 Academic Press Inc.","journal-title":"Mol Genet Metab"},{"key":"620_CR61","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ymgme.2016.04.005","volume":"118","author":"E Yasuda","year":"2016","unstructured":"Yasuda E, Suzuki Y, Shimada T, Sawamoto K, Mackenzie WG, Theroux MC, et al. Activity of daily living for Morquio A syndrome. Mol Genet Metab. 2016;118:111\u201322 Academic Press Inc.","journal-title":"Mol Genet Metab"},{"key":"620_CR62","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s10038-019-0604-6","volume":"64","author":"C Doherty","year":"2019","unstructured":"Doherty C, Stapleton M, Piechnik M, Mason RW, Mackenzie WG, Yamaguchi S, et al. Effect of enzyme replacement therapy on the growth of patients with Morquio A. J Hum Genet. 2019;64:625\u201335 Nature Publishing Group.","journal-title":"J Hum Genet"},{"key":"620_CR63","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ymgme.2015.09.011","volume":"117","author":"H Yabe","year":"2016","unstructured":"Yabe H, Tanaka A, Chinen Y, Kato S, Sawamoto K, Yasuda E, et al. Hematopoietic stem cell transplantation for Morquio A syndrome. Mol Genet Metab. 2016;117:84\u201394 [Internet]. Academic Press Inc.; [cited 2020 Apr 17]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26452513.","journal-title":"Mol Genet Metab"},{"key":"620_CR64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ymgmr.2013.11.002","volume":"1","author":"Y Chinen","year":"2014","unstructured":"Chinen Y, Higa T, Tomatsu S, Suzuki Y, Orii T, Hyakuna N. Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA. Mol Genet Metab Rep. 2014;1:31\u201341 Elsevier Inc.","journal-title":"Mol Genet Metab Rep"},{"key":"620_CR65","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/mt.2010.32","volume":"18","author":"S Tomatsu","year":"2010","unstructured":"Tomatsu S, Mont\u00e3o AM, Dung VC, Ohashi A, Oikawa H, Oguma T, et al. Enhancement of drug delivery: enzyme-replacement therapy for murine morquio a syndrome. Mol Ther. 2010;18:1094\u2013102.","journal-title":"Mol Ther"},{"key":"620_CR66","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1093\/hmg\/ddm353","volume":"17","author":"S Tomatsu","year":"2008","unstructured":"Tomatsu S, Monta\u00f1o AM, Ohashi A, Gutierrez MA, Oikawa H, Oguma T, et al. Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet. 2008;17:815\u201324. [Internet]. Available from. https:\/\/doi.org\/10.1093\/hmg\/ddm353.","journal-title":"Hum Mol Genet"},{"key":"620_CR67","doi-asserted-by":"crossref","unstructured":"V\u00edctor \u00c1lvarez J, Bravo SB, Garc\u00eda-Vence M, De Castro MJ, Luzardo A, Col\u00f3n C, et al. Proteomic analysis in morquio a cells treated with immobilized enzymatic replacement therapy on nanostructured lipid systems. Int J Mol Sci. 2019;20 MDPI AG.","DOI":"10.3390\/ijms20184610"},{"key":"620_CR68","doi-asserted-by":"crossref","unstructured":"Sawamoto K, Gonz\u00e1lez JV\u00c1, Piechnik M, Otero FJ, Couce ML, Suzuki Y, et al. Mucopolysaccharidosis IVA: diagnosis, treatment, and management. Int J Mol Sci. 2020; MDPI AG.","DOI":"10.3390\/ijms21041517"},{"key":"620_CR69","doi-asserted-by":"crossref","unstructured":"Nishioka T, Tomatsu S, Gutierrez MA, Miyamoto K, Trandafirescu GG, Lopez PLC, et al. Enhancement of drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide [Internet]. Mol Genet Metab. 2006:244\u201355 Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1096719206000758.","DOI":"10.1016\/j.ymgme.2006.02.012"},{"key":"620_CR70","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bone.2017.02.011","volume":"102","author":"MP Whyte","year":"2017","unstructured":"Whyte MP. Hypophosphatasia: an overview for 2017. Bone. 2017;102:15\u201325 Center for Metabolic Bone Disease and Molecular Research, Shriners Hospital for Children, Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine at Barnes-Jewish Hospital, St. Louis, Missouri, USA.: Elsevier Inc.","journal-title":"Bone"},{"key":"620_CR71","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/jbmr.3075","volume":"32","author":"MP Whyte","year":"2017","unstructured":"Whyte MP. Hypophosphatasia: enzyme replacement therapy brings new opportunities and new challenges. J Bone Miner Res. 2017;32:667\u201375. [Internet]. John Wiley & Sons, Ltd. Available from. https:\/\/doi.org\/10.1002\/jbmr.3075.","journal-title":"J Bone Miner Res"},{"key":"620_CR72","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12018-013-9140-7","volume":"11","author":"E Mornet","year":"2013","unstructured":"Mornet E. Genetics of Hypophosphatasia. Clin Rev Bone Miner Metab. 2013;11:71\u20137. [Internet]. Available from. https:\/\/doi.org\/10.1007\/s12018-013-9140-7.","journal-title":"Clin Rev Bone Miner Metab"},{"key":"620_CR73","doi-asserted-by":"crossref","unstructured":"Castells L, Cassanello P, Mu\u00f1iz F, De Castro MJ, Couce ML. Neonatal lethal hypophosphatasia A case report and review of literature. Medicine. 2018:97 Lippincott Williams and Wilkins.","DOI":"10.1097\/MD.0000000000013269"},{"key":"620_CR74","unstructured":"Whyte MP, Habib D, Coburn SP, Tecklenburg F, Ryan LM, Fedde K, et al. Failure of hyper-phosphatasemia by intravenous infusion of purified placental alkaline phosphatase (ALP) to correct severe hypophosphatasia: evidence against. J Bone Miner Res. 1992;7."},{"key":"620_CR75","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1172\/JCI117814","volume":"95","author":"MP Whyte","year":"1995","unstructured":"Whyte MP, Landt M, Ryan LM, Mulivor RA, Henthorn PS, Fedde KN, et al. Alkaline phosphatase: placental and tissue-nonspecific isoenzymes hydrolyze phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5\u2019-phosphate. Substrate accumulation in carriers of hypophosphatasia corrects during pregnancy. J Clin Invest. 1995;95:1440\u20135 Metabolic Research Unit, Shriners Hospital for Crippled Children, St. Louis, Missouri 63131, USA.","journal-title":"J Clin Invest"},{"key":"620_CR76","first-page":"82","volume":"108","author":"MP Whyte","year":"1986","unstructured":"Whyte MP, Magill HL, Fallon MD, Herrod HG. Infantile hypophosphatasia: normalization of circulating bone alkaline phosphatase activity followed by skeletal remineralization. Evidence for an intact structural gene for tissue nonspecific alkaline phosphatase. J Pediatr United States. 1986;108:82\u20138.","journal-title":"J Pediatr United States"},{"key":"620_CR77","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.metabol.2017.08.013","volume":"82","author":"E Mornet","year":"2018","unstructured":"Mornet E. Hypophosphatasia. Metabolism. 2018;82:142\u201355 Unite de Genetique Constitutionnelle, Service de Biologie, Centre Hospitalier de Versailles, 177 rue de Versailles, 78150 Le Chesnay, France. Electronic address: emornet@ch-versailles.fr.: Elsevier Inc.","journal-title":"Metabolism"},{"key":"620_CR78","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00223-015-0079-1","volume":"98","author":"JL Millan","year":"2016","unstructured":"Millan JL, Whyte MP. Alkaline phosphatase and hypophosphatasia. Calcif Tissue Int. 2016;98:398\u2013416 Sanford Children\u2019s Health Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA. millan@burnham.org.; Center for Metabolic Bone Disease and Molecular Research, Shriners Hospital for Children, St. Louis, MO, 63110, U.","journal-title":"Calcif Tissue Int"},{"key":"620_CR79","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ymgme.2019.05.014","volume":"127","author":"C Nakano","year":"2019","unstructured":"Nakano C, Kitabatake Y, Takeyari S, Ohata Y, Kubota T, Taketani K, et al. Genetic correction of induced pluripotent stem cells mediated by transcription activator-like effector nucleases targeting ALPL recovers enzyme activity and calcification in vitro. Mol Genet Metab. 2019;127:158\u201365 [Internet]. Academic Press Inc.; [cited 2020 Apr 20]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31178256.","journal-title":"Mol Genet Metab"},{"key":"620_CR80","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1089\/hum.2010.210","volume":"22","author":"T Matsumoto","year":"2011","unstructured":"Matsumoto T, Miyake K, Yamamoto S, Orimo H, Miyake N, Odagaki Y, et al. Rescue of severe infantile hypophosphatasia mice by AAV-mediated sustained expression of soluble alkaline phosphatase. Hum Gene Ther. 2011;22:1355\u201364 Department of Biochemistry and Molecular Biology, Nippon Medical School, Bunkyo-ku, Tokyo 113\u20138602, Japan.","journal-title":"Hum Gene Ther"},{"key":"620_CR81","doi-asserted-by":"crossref","unstructured":"Nakamura-Takahashi A, Miyake K, Watanabe A, Hirai Y, Iijima O, Miyake N, et al. Treatment of hypophosphatasia by muscle-directed expression of bone-targeted alkaline phosphatase via self-complementary AAV8 vector [Internet]. Mol Ther Methods Clin Dev. 2016:15059 Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S2329050116301498.","DOI":"10.1038\/mtm.2015.59"},{"key":"620_CR82","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/jbmr.201","volume":"26","author":"S Yamamoto","year":"2011","unstructured":"Yamamoto S, Orimo H, Matsumoto T, Iijima O, Narisawa S, Maeda T, et al. Prolonged survival and phenotypic correction of Akp2\u2212\/\u2212 hypophosphatasia mice by lentiviral gene therapy. J Bone Miner Res. 2011;26:135\u201342. [Internet]. John Wiley & Sons, Ltd. Available from. https:\/\/doi.org\/10.1002\/jbmr.201.","journal-title":"J Bone Miner Res"},{"key":"620_CR83","doi-asserted-by":"crossref","unstructured":"Ikeue R, Nakamura-Takahashi A, Nitahara-Kasahara Y, Watanabe A, Muramatsu T, Sato T, et al. Bone-targeted alkaline phosphatase treatment of mandibular bone and teeth in lethal hypophosphatasia via an scAAV8 Vector [Internet]. Mol Ther Methods Clin Dev. 2018:361\u201370 Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S2329050118300810.","DOI":"10.1016\/j.omtm.2018.08.004"},{"key":"620_CR84","unstructured":"Nakamura-Takahashi A, Tanase T, Matsunaga S, Shintani S, Abe S, Nitahara-Kasahara Y, et al. High-level expression of alkaline phosphatase by adeno-associated virus vector ameliorates pathological bone structure in a hypophosphatasia mouse model. Calcif Tissue Int. 2020; Department of Pharmacology, Tokyo Dental College, 2-9-18, Kandamisaki-cho, Chiyoda-ku, Tokyo, 101-0061, Japan. atakahashi@tdc.ac.jp.; Tokyo Dental College Research Branding Project, Tokyo Dental College, Tokyo, Japan. atakahashi@tdc.ac.jp.; Department of."},{"key":"620_CR85","doi-asserted-by":"publisher","first-page":"6782653","DOI":"10.1155\/2019\/6782653","volume":"2019","author":"X Sun","year":"2019","unstructured":"Sun X, Guo Q, Wei W, Robertson S, Yuan Y, Luo X. Current progress on microRNA-based gene delivery in the treatment of osteoporosis and osteoporotic fracture. Dufau ML, editor. Int J Endocrinol. 2019;2019:6782653. [Internet]. Hindawi. Available from. https:\/\/doi.org\/10.1155\/2019\/6782653.","journal-title":"Int J Endocrinol"},{"key":"620_CR86","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1038\/s41467-019-10809-6","volume":"10","author":"Y-S Yang","year":"2019","unstructured":"Yang Y-S, Xie J, Wang D, Kim J-M, Tai PWL, Gravallese E, et al. Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis. Nat Commun. 2019;10:2958. [Internet]. Available from. https:\/\/doi.org\/10.1038\/s41467-019-10809-6.","journal-title":"Nat Commun"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-020-00620-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11914-020-00620-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-020-00620-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T23:23:16Z","timestamp":1629933796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11914-020-00620-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["620"],"URL":"https:\/\/doi.org\/10.1007\/s11914-020-00620-4","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,26]]},"assertion":[{"value":"26 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}